What is HC Wainwright's Estimate for AURA Q1 Earnings?

Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) - HC Wainwright issued their Q1 2025 earnings estimates for shares of Aura Biosciences in a report issued on Tuesday, March 25th. HC Wainwright analyst E. White forecasts that the company will earn ($0.44) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $22.00 price objective on the stock. The consensus estimate for Aura Biosciences' current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Aura Biosciences' Q2 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.87) EPS and FY2026 earnings at ($2.11) EPS.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last posted its earnings results on Monday, March 24th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.09).

Separately, Lifesci Capital raised Aura Biosciences to a "strong-buy" rating in a report on Friday, January 31st. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $23.00.

Aura Biosciences Trading Down 7.8 %

Shares of NASDAQ AURA traded down $0.50 during trading hours on Thursday, reaching $5.85. The stock had a trading volume of 52,995 shares, compared to its average volume of 189,332. The firm has a 50-day moving average of $7.54 and a 200-day moving average of $8.60. The firm has a market cap of $293.57 million, a price-to-earnings ratio of -3.39 and a beta of 0.30. Aura Biosciences has a fifty-two week low of $5.77 and a fifty-two week high of $12.38.

Remove Ads

Institutional Investors Weigh In On Aura Biosciences

Several institutional investors and hedge funds have recently modified their holdings of AURA. Long Focus Capital Management LLC increased its stake in Aura Biosciences by 123.9% during the 4th quarter. Long Focus Capital Management LLC now owns 2,537,774 shares of the company's stock worth $20,861,000 after buying an additional 1,404,228 shares during the period. Vanguard Group Inc. boosted its holdings in Aura Biosciences by 6.2% in the fourth quarter. Vanguard Group Inc. now owns 1,917,730 shares of the company's stock valued at $15,764,000 after purchasing an additional 112,296 shares during the last quarter. Franklin Resources Inc. grew its stake in Aura Biosciences by 3.2% during the 4th quarter. Franklin Resources Inc. now owns 1,723,063 shares of the company's stock valued at $14,164,000 after purchasing an additional 54,103 shares in the last quarter. Levin Capital Strategies L.P. raised its position in shares of Aura Biosciences by 169.1% in the 4th quarter. Levin Capital Strategies L.P. now owns 1,247,619 shares of the company's stock valued at $10,255,000 after purchasing an additional 783,984 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Aura Biosciences by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 1,012,799 shares of the company's stock valued at $8,327,000 after buying an additional 3,972 shares during the last quarter. Hedge funds and other institutional investors own 96.75% of the company's stock.

Insiders Place Their Bets

In other Aura Biosciences news, insider Los Pinos Elisabet De sold 15,955 shares of the business's stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total transaction of $122,374.85. Following the completion of the sale, the insider now directly owns 304,692 shares in the company, valued at $2,336,987.64. The trade was a 4.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last three months, insiders sold 23,045 shares of company stock valued at $177,242. Company insiders own 5.40% of the company's stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.